Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

Bullboard (GREY:IPHAF)

View:
Post by culateron Sep 29, 2010 1:18pm

Goldman

back at it.   Somebody wants to own a lot of this stock !culater
Comment by Plato5on Sep 29, 2010 10:13am

RE: in lieu of news...

Yes we need something to point to - the European approval process for uveitis is the only one I am aware of now. But what the hell has happened with the FDA response. This dire lack of information is ...more  
Post by antoninuson Sep 28, 2010 8:15am

in lieu of news...

what are the timelines....???psoriasis? what countries and what timeframes?same for TX.same for uveitissame for stentssame for tafaetc..etc...
Comment by MementoMorion Sep 25, 2010 1:22am

RE: RE: RE: David has grea texperience. Go See

> @font-face { font-family: "Times"; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0cm 0cm 0.0001pt; font-size: 12pt; font-family: Times; }div.Section1 { page: Section1 ...more  
Post by antoninuson Sep 24, 2010 3:38pm

I would prefer francisco bellini

either way, foster is not the man for this job.I'm just hoping that in 1-2 years this stock is in the 3-4 dollar range.I suspect that a takeover will emerge at something far lower. I hope not ...more  
Comment by labumbaon Sep 24, 2010 3:33pm

RE: RE: RE: David has grea texperience. Go See

I should have said ' Pez alike to run this stock "  or " a fellow with that kind caliber to run this stock.......frankly, we do need a good promoter for this company.....not ...more  
Comment by ngerritson Sep 24, 2010 3:23pm

RE: sold some kept some

I wonder why Goldman Sachs has bought about 1M shares at around .35 the last 3 weeks if its dead money.
Post by klank37on Sep 24, 2010 12:14pm

sold some kept some

I did my usual call to the company and it appear to me that it isn't anytime soon (1 year) before anything of substance will happen. No enrollment for the new trial is on the way, european not ...more  
Post by ISAloser247on Sep 23, 2010 11:29am

RE:......

...........IS IT IN THE 3-RD QUARTER, VALUE-ADDING , NEWS EVENTS ANNOUNCED BY R.F.?
Post by labumbaon Sep 22, 2010 9:33pm

.......

I didn't see one share bought from these guys in the open market......where is the beef ?
Comment by labumbaon Sep 21, 2010 10:14pm

RE: David has grea texperience. Go See

we need Murray Pezim to run this stock
Post by velleon Sep 21, 2010 8:10pm

David has grea texperience. Go See

https://ca.linkedin.com/pub/david-macnaughtan/5/a61/7a0
Post by blogon Sep 21, 2010 3:56pm

New guy

The new guy is a deal maker.M. David MacNaughtan, M.Sc., M.B.A.Chairman of the Board
Post by ngerritson Sep 17, 2010 12:19pm

China Market

Explosive Chinese market inspires new Merck pact on personalized meds September 17, 2010 — 9:43am ET | By John Carroll With the ...more  
Post by bmoron Sep 14, 2010 9:15pm

3SBio Announces Partial Conversion of Isotechnika

https://www.prnewswire.com/news-releases/3sbio-announces-partial-conversion-of-isotechnika-debenture-102918224.html
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities